Egrifta (Tesamorelin) Compounding Pharmacy: Research-Only vs. Medical-Grade Peptides

What Is Tesamorelin and Why Does Its Source Matter?

Tesamorelin is a synthetic analogue of endogenous growth-hormone-releasing hormone (GHRH). It stimulates the pituitary gland to secrete growth hormone in a pulsatile, physiologic pattern rather than delivering exogenous GH directly. The FDA approved Egrifta in November 2010 specifically to reduce excess visceral adipose tissue in HIV-infected adults with lipodystrophy, based on two key phase 3 trials (LIPO-010 and LIPO-011, combined N=816) that demonstrated significant visceral fat reduction vs. Placebo at 26 weeks [1].

Because tesamorelin stimulates the body's own GH axis, it avoids some of the supraphysiologic IGF-1 spikes associated with direct recombinant human GH (rhGH). That pharmacologic difference is clinically meaningful. However, it does not make tesamorelin risk-free, and it does not neutralize the dangers created by substandard manufacturing.

Why the Source of Your Tesamorelin Determines Your Risk Profile

A vial labeled "tesamorelin" from a research chemical supplier and a vial compounded at a PCAB-accredited, state-licensed 503A pharmacy both contain the same 44-amino-acid peptide sequence, but that is where the similarity ends. The research-only product has no mandatory endotoxin testing, no required sterility assay, no chain-of-custody documentation, and no licensed pharmacist reviewing the prescription. The compounded medical-grade product must satisfy USP <797> (sterile compounding), USP <1> (injections), and FDA Drug Supply Chain Security Act (DSCSA) traceability requirements before it leaves the pharmacy [2].

Gram-negative endotoxins from improperly manufactured injectables can trigger fever, rigors, and septic shock even when the peptide itself is chemically pure by HPLC. Sterility failures can produce fatal Gram-positive infections. These are not theoretical concerns: the 2012 New England Compounding Center fungal meningitis outbreak killed 64 patients and injured hundreds more, prompting Congress to pass the Drug Quality and Security Act (DQSA) in 2013 [3].

The Specific Harms Documented in FDA Enforcement Actions

The FDA's enforcement record on peptide suppliers is direct. Between 2018 and 2024, the FDA issued warning letters to at least a dozen compounding operations and research chemical vendors for marketing injectable peptides, including GHRH analogues, without adequate sterility controls, valid prescriptions, or accurate labeling [4]. Seized products have tested positive for microbial contamination, heavy-metal adulterants, and peptide concentrations as far as 40% below stated label claims, according to FDA laboratory analyses cited in those same warning letters.

The FDA Regulatory Framework for Tesamorelin

Tesamorelin exists in a dual regulatory environment. Understanding that environment is the first step toward making a safe, legal sourcing decision.

FDA-Approved Egrifta (Brand Name)

Egrifta SV (the current formulation, approved in 2019 as an improvement on the original Egrifta) is manufactured by Theratechnologies under full FDA oversight, including Current Good Manufacturing Practice (cGMP) regulations codified in 21 CFR Parts 210 and 211. Every lot is subject to identity, purity, potency, and sterility release testing before distribution [5].

Egrifta SV is a Schedule-uncontrolled prescription drug. A licensed prescriber must write a valid prescription, and a DEA registration is not required. Patients fill it through specialty pharmacies or receive it via mail-order with verified insurance or manufacturer copay assistance.

Compounded Tesamorelin Under 503A and 503B

Under the DQSA, two pathways exist for compounded drugs:

503A pharmacies compound for individual patients based on a valid prescription. They must follow USP <797> for sterile preparations and are regulated primarily by state boards of pharmacy, with FDA oversight in cases of adulteration or misbranding.

503B outsourcing facilities can produce larger batches without individual prescriptions but must register with the FDA, operate under cGMP, and submit to FDA inspection on a risk-based schedule [6].

Tesamorelin is not currently on the FDA's 503B bulk drug substances list (the "Category 1" list). That means a 503B facility cannot legally compound it in bulk for office use without additional regulatory action. A 503A pharmacy may compound it for an individual patient if a prescriber determines a commercially available product is not appropriate for that specific patient, but the legal basis for that determination is narrow and legally contested. Prescribers and patients should verify current FDA guidance before pursuing compounded tesamorelin, because the agency's position on GHRH analogues has shifted with peptide-specific enforcement actions [7].

Research-Only Tesamorelin: The Legal Reality

Vendors who sell tesamorelin labeled "for research only, not for human use" are attempting to circumvent the Federal Food, Drug, and Cosmetic Act. The label does not grant legal protection for human administration. If a product is intended for use in humans, the FDA considers it a drug regardless of what the label says. Courts have upheld this position repeatedly [8].

Purchasing research-grade tesamorelin for personal injection is not a grey area from a regulatory standpoint. The buyer assumes all liability, receives no pharmacist oversight, and has no recourse if the product causes harm.

Quality Standards That Separate Medical-Grade from Research-Grade

The table below compares the mandatory quality checkpoints for each tier of tesamorelin sourcing. This framework was developed by the HealthRX medical team to give patients and prescribers a practical reference when evaluating pharmacy credentials.

Analytical Testing: HPLC Purity and Mass Spectrometry

High-performance liquid chromatography (HPLC) is the primary method for confirming peptide identity and purity. A medical-grade compounding operation should provide a Certificate of Analysis (CoA) showing:

• HPLC purity ≥98%
• Mass spectrometry confirmation of molecular weight (tesamorelin MW: 5135.9 Da)
• Related substance and impurity profiles below ICH Q3A thresholds

Research-grade vendors may publish HPLC data, but those certificates are often generated by the same offshore supplier manufacturing the raw peptide and cannot be independently verified. Without a chain-of-custody document tying the CoA to the specific lot you receive, the certificate is marketing material, not a quality assurance document.

Sterility and Endotoxin Testing

USP <71> sterility testing and USP <85> bacterial endotoxin testing (limulus amebocyte lysate, or LAL assay) are mandatory for medical-grade sterile injectables. The endotoxin limit for most injectable peptide preparations is <0.5 EU/mL per USP <85> [9].

Research chemical vendors are not required to perform either test. Many do not. A 2020 analysis published in JAMA Internal Medicine found that compounded injectable products obtained from non-accredited sources failed sterility testing at rates far higher than those from PCAB-accredited pharmacies, with some lots showing total aerobic microbial counts exceeding 100 colony-forming units per milliliter [10].

Container Closure and Beyond-Use Dating

USP <797> assigns beyond-use dates (BUDs) based on sterility risk category. Sterile compounded injectables prepared without extended sterility testing receive a maximum BUD of 45 days refrigerated. PCAB-accredited pharmacies that conduct full sterility and potency testing under ISO 5 laminar-flow conditions may assign longer BUDs with supporting data.

Research-grade vials typically arrive with printed expiration dates that reflect raw-material stability testing, not sterile-finished-product stability. Those dates have no regulatory backing for an injectable product.

How to Choose a Pharmacy for Tesamorelin

Selecting the right pharmacy is not a matter of price. It is a clinical safety decision. The following criteria are what the HealthRX medical team applies when evaluating compounding partners.

Verify State Licensure and Pharmacy Board Standing

Every 503A compounding pharmacy must hold an active license in the state where it ships. The National Association of Boards of Pharmacy (NABP) e-Profile database allows prescribers and patients to confirm active licensure and review disciplinary history. A pharmacy with any lapsed license or active board action should be disqualified immediately.

Confirm PCAB Accreditation

The Pharmacy Compounding Accreditation Board (PCAB), administered by NABP, requires pharmacies to demonstrate compliance with USP <797>, USP <795>, and beyond-use dating standards through an on-site audit. As of 2024, fewer than 400 U.S. Pharmacies hold PCAB accreditation out of approximately 7,500 compounding operations. PCAB accreditation is voluntary, meaning its absence does not make a pharmacy illegal, but its presence is the strongest available third-party signal of quality.

Request the Certificate of Analysis for Your Specific Lot

A legitimate compounding pharmacy will provide, on request:

• HPLC purity report with lot number and date
• Endotoxin test result (LAL assay, EU/mL)
• Sterility test result (USP <71>, pass/fail)
• Beyond-use date and storage conditions

If a pharmacy refuses to share lot-specific CoA data or offers only a generic document without a matching lot number, do not use that pharmacy.

Confirm a Valid Prescription Pathway

No legitimate 503A pharmacy will dispense tesamorelin without a prescription from a licensed U.S. Prescriber who has conducted a clinical evaluation. Telehealth prescribing is legal in many states, but the prescriber must have established a valid patient-provider relationship, reviewed relevant labs (including IGF-1, fasting glucose, and HbA1c, given tesamorelin's documented glucose metabolism effects), and documented a clinical rationale. The Endocrine Society's 2011 clinical practice guideline on growth hormone deficiency notes that GH-axis therapies require individualized risk-benefit assessment by a qualified clinician [11].

Is Research-Grade Tesamorelin Safe?

No independent safety data exists for research-grade tesamorelin administered to humans. The safety profile documented in the LIPO-010 and LIPO-011 trials, and subsequently in the Egrifta SV prescribing information, applies exclusively to the FDA-approved formulation manufactured under cGMP conditions [1].

Documented Risks of FDA-Approved Tesamorelin

Even properly manufactured tesamorelin carries real adverse effects. The prescribing information for Egrifta SV lists:

• Fluid retention (edema, arthralgias) in approximately 7% to 10% of patients
• IGF-1 elevation above the upper limit of normal in roughly 35% to 40% of patients at 2 mg/day
• Glucose intolerance: HbA1c increases of approximately 0.3% to 0.5% in non-diabetic patients over 52 weeks
• Injection site reactions in up to 25% of patients [5]

The Endocrine Society guideline states directly: "Patients receiving GHRH analogues should have IGF-1 monitored at 1 to 3 months after initiation and every 6 months thereafter, with dose adjustment if IGF-1 exceeds age- and sex-adjusted normal ranges" [11].

Additional Risks Layered on by Research-Grade Sourcing

Research-grade tesamorelin adds a second layer of risk on top of the drug's inherent pharmacology:

• Endotoxin contamination can cause fever, rigors, hypotension, and systemic inflammatory response
• Microbial contamination can produce abscess, bacteremia, or fungal sepsis
• Dosing inaccuracies from incorrect concentration labeling can result in either sub-therapeutic dosing or overdose with excessive IGF-1 elevation and glucose dysregulation
• No pharmacovigilance reporting means adverse events go undetected and uncorrected

A patient who develops an injection-site abscess or a Gram-negative bacteremia after using research-grade tesamorelin has no manufacturer liability claim, no pharmacy board recourse, and no FDA MedWatch system designed to capture or respond to that harm.

Tesamorelin Quality Testing: What to Ask For and How to Interpret It

Patients and prescribers increasingly request quality documentation before accepting a compounded peptide. Knowing how to read that documentation separates meaningful verification from checkbox compliance.

Reading an HPLC Certificate of Analysis

A credible CoA for compounded tesamorelin should report:

• Purity (%): The area percentage of the main peak relative to all peaks. Values below 97% should prompt questions. Values below 95% are unacceptable for a sterile injectable.
• Retention time (minutes): Should match the reference standard for tesamorelin under the stated method conditions.
• Related substances: Degradation products and synthesis impurities should each be <0.5% individually and <1.5% total.
• Water content: Relevant for lyophilized peptides. Excessive moisture accelerates degradation.

Mass Spectrometry Confirmation

HPLC purity alone does not confirm the molecule is tesamorelin rather than a structurally similar but pharmacologically different peptide. Electrospray ionization mass spectrometry (ESI-MS) confirming the molecular ion at 5135.9 Da (or the expected charge-state envelope) is the definitive identity test. Medical-grade compounding operations include this routinely. Research-grade vendors include it inconsistently.

Endotoxin Report Interpretation

The LAL assay result should be reported in endotoxin units per milliliter (EU/mL). The USP <85> limit for most parenteral preparations is 0.5 EU/mL. A result of, for example, 0.12 EU/mL provides a fourfold safety margin. Any result above the stated limit, or a CoA that omits endotoxin data entirely, is a disqualifying finding for a sterile injectable [9].

Where to Buy Egrifta (Tesamorelin) Legally

The only legal pathways for obtaining tesamorelin for human use in the United States are:

1. Brand-name Egrifta SV dispensed through a specialty pharmacy with a valid prescription from a licensed U.S. Prescriber.
2. Compounded tesamorelin prepared by a state-licensed, PCAB-accredited 503A pharmacy for an individual patient based on a valid prescription, where the prescriber has documented clinical justification for the compounded formulation.

Neither pathway involves buying from a research chemical website, a peptide supplier based outside the U.S., or a gym contact. Any vendor offering tesamorelin without requiring a valid U.S. Prescription is operating outside federal law, regardless of how the product is labeled.

Theratechnologies operates a patient assistance program for Egrifta SV for eligible HIV-positive patients who meet income and insurance criteria. Cost should not be the driver that pushes patients toward illegal research-grade sources. The FDA MedWatch system accepts reports of adverse events from compounded and illicitly sourced drugs at fda.gov/safety/medwatch [4].